1. 3 potential blockbusters under FDA review — AbbVie gets the most out of its workers — Roche/Exelixis’ Cotellic fizzles in melanoma study — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Product payout

Discussion in 'BioDelivery Sciences' started by anonymous, Aug 20, 2018 at 5:45 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    how are reps payout between belbuca and bunavail? 50/50? What does the future look like for BDSI? What will a generic addiction film do to bunavail?
     

  2. anonymous

    anonymous Guest

    This is the story genius, no one would notice a generic.

    Summary of Second Quarter 2018 Financial Results

    Total net revenue. Total net revenue for the second quarter ended June 30, 2018, was $12.2 million, compared to $11.3 million in the first quarter of 2018, an increase of 8%, and $8.7 million in the second quarter of 2017, an increase of 39%.

    Total product net revenue. Total product net revenue for BELBUCA® (buprenorphine) buccal film and BUNAVAIL® (buprenorphine and naloxone) buccal film in the second quarter ended June 30, 2018, was $9.7 million and $1.1 million, respectively, versus $8.0 million and $1.8 million, respectively, in the first quarter of 2018, and $6.6 million and $1.3 million, respectively, in the second quarter of 2017.

    Total operating expenses. Total operating expenses for the second quarter ended June 30, 2018, were $14.9 million, compared to $16.0 million in the first quarter of 2018, and $17.6 million in the second quarter of 2017.

    Net loss. Net loss for the second quarter ended June 30, 2018, was $9.8 million, or ($0.16) per diluted share, compared to a net loss of $10.7 million, or ($0.18) per diluted share, in the first quarter of 2018; and a net loss of $14.9 million, or ($0.27) per diluted share, in the second quarter of 2017.
     
  3. anonymous

    anonymous Guest


    You guys are expanding and someone asks a legitimate question and this is the response? Hey genius, is everyone at BDSI an arrogant jerk or just you?
     
  4. anonymous

    anonymous Guest

    Na, pretty much everyone.
     
  5. anonymous

    anonymous Guest

    We dont need any more dummies who cant sell
     
  6. anonymous

    anonymous Guest

    Daytrader here: all the dummies you guys are hiring have less than a year with the company and little to no pharmaceutical experience. You guys are slowly killing the confidence of your investors especially if you guys claim you hire are dummies not sure this is where I want to invest my money.